M&A / Deals Isomorphic Labs receives $2.1bn for AI drug development Pharmaceutical TechnologyIsomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Makary resigns, with Diamantas named as acting FDA commissionerNext: Novo, Lilly trade oral GLP-1 data readouts at ECO Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
